Sherry Weigand

Sherry Weigand, MD, PhD, is a highly experienced medical professional specializing in immunology and microbiome therapy. Currently serving as Senior Vice President and Head of Clinical Science at Seres Therapeutics since December 2017, Sherry Weigand focuses on developing microbiome therapies for Ulcerative Colitis. In parallel, Sherry holds the position of Global Development Lead and Senior Medical Director in Immunology at Shire, addressing immune-mediated inflammatory diseases, and has previously worked at Baxalta and Takeda Pharmaceuticals, leading programs in various immunological and inflammatory conditions. Sherry Weigand's career began at Procter and Gamble Pharmaceuticals and includes significant research contributions at the University of Pittsburgh School of Medicine and clinical practice at Beijing ChaoYang Hospital. Sherry Weigand holds a Ph.D. in Microbiology and Immunology from Louisiana State University and an MBBS from Beijing Medical School.